← Back to Trade Analysis Quick Facts
| Metric | Value |
|---|
| US Import Rank | #12 |
| 2024 Import Value | ~$70 billion |
| % of US Imports | 2.1% |
| 2024 Tariff Rate | ~2.5% average |
| Current Tariff Rate | 10% (lowest major partner) |
| Trade Agreement | US-UK Economic Prosperity Deal |
| US Trade Balance | +$12 billion surplus |
Trade Agreement
Previous Status (Post-Brexit)
After Brexit (January 2020), the UK traded with the US under:
- WTO Most Favored Nation (MFN) rules
- No comprehensive FTA
- Bilateral negotiations stalled under Biden
US-UK Economic Prosperity Deal (EPD)
| Date | Event |
|---|
| May 8, 2025 | Announced by Trump and Starmer |
| June 16, 2025 | Formally signed at G7 Summit (Canada) |
| June 30, 2025 | First provisions enter into force |
Nature: Non-binding framework agreement, not a full FTA
Key Terms
| Area | US Offer | UK Concession |
|---|
| General tariff | 10% (vs. 15% for EU) | — |
| Automobiles | 10% (100K quota) | Beef quota: 13K tonnes |
| Aerospace | 0% | Ethanol: 1.4B liters duty-free |
| Pharmaceuticals | 0% (3 years) | 25% more pharma spending |
| Steel/aluminum | 25% → 0% (pending quota) | — |
2024 Baseline Tariff Structure
| Product Category | 2024 Rate | Notes |
|---|
| Most goods | ~2.5% | MFN rates |
| Automobiles | 2.5% | Pre-tariff |
| Steel | 25% | Section 232 with quota |
| Aluminum | 10% | Section 232 |
2025 Tariff Changes
Timeline
Apr 5, 2025 "Liberation Day" - 10% reciprocal tariff on UK
May 8, 2025 Economic Prosperity Deal announced
Jun 16, 2025 EPD formally signed
Jun 30, 2025 EPD provisions take effect
Dec 1, 2025 Pharmaceutical pricing agreement
Dec 16, 2025 Tech Prosperity Deal suspended (DST dispute)
Current Tariff Structure (January 2026)
| Product Category | Current Rate | Notes |
|---|
| General goods | 10% | EPD rate (lowest) |
| Steel | 25% | Pending 0% quota |
| Aluminum | 25% | Pending 0% quota |
| Automobiles | 10% | Within 100K quota |
| Over-quota vehicles | 27.5% | Exceeding quota |
| Aerospace | 0% | Exempt |
| Pharmaceuticals | 0% | 3-year exemption |
| Medical technology | 0% | Included with pharma |
Exemptions
Aerospace (0%)
| Product | Status |
|---|
| Civil aircraft | Exempt |
| Components | Exempt |
| Engines | Exempt |
Major beneficiary: Rolls-Royce, aerospace supply chain
Pharmaceuticals (0% for 3 years)
| Provision | Detail |
|---|
| Duration | 3 years (through 2028) |
| Coverage | Generic and branded |
| UK commitment | 25% increase in pharma spending |
| Agreement date | December 1, 2025 |
Medical Technology
Included with pharmaceutical exemption
The UK’s Favorable Treatment
Why 10% Instead of 15% (EU)?
| Factor | Explanation |
|---|
| Post-Brexit flexibility | Not bound by EU common policy |
| ”Special relationship” | Historical US-UK ties |
| Quick negotiation | Starmer government moved fast |
| Strategic value | Intelligence sharing, defense |
| Concessions offered | Beef, ethanol, pharma pricing |
UK vs. EU Comparison
| Category | UK Rate | EU Rate |
|---|
| General goods | 10% | 15% |
| Automobiles | 10% | 15% |
| Wine | 10% | 15% |
| Aerospace | 0% | 0% |
| Pharma | 0% | 0% (generics only) |
Economic Effects
GDP Impact
| Source | Projection |
|---|
| Oxford Economics | Growth reduced to 1.0% (2025) |
| 2026 projection | 0.9% |
| Without escalation | ~0.3% GDP impact |
Export Impact
| Metric | Change |
|---|
| UK exports to US (Sept 2025) | Down £0.5 billion (11.4%) |
| September 2025 level | Lowest since January 2022 |
Business Survey (November 2025)
| Finding | Percentage |
|---|
| Businesses affected by tariffs | 34% |
| Reporting additional costs | 22% |
| Expecting lower sales | 27% |
| Expecting no sales impact | 70% |
Employment Concerns
| Sector | Jobs at Risk |
|---|
| Automotive | 25,000 |
| Jaguar Land Rover | High exposure |
| Mini | High exposure |
Key Products Affected
Automobiles (£7.6 billion - 15% of UK exports to US)
| Status | Tariff |
|---|
| Within quota (100K units) | 10% |
| Over quota | 27.5% |
Major Brands:
- Jaguar Land Rover
- Mini (BMW)
- Bentley (VW)
- Aston Martin
- McLaren
Pharmaceuticals (£11.1 billion - 11% of exports)
| Status | Tariff |
|---|
| All pharma | 0% (3-year exemption) |
Major Companies:
- GlaxoSmithKline
- AstraZeneca
Steel (£370 million)
| Status | Detail |
|---|
| Current tariff | 25% |
| Future | 0% under quota (being negotiated) |
| UK steel share | 7% of UK steel exports |
Whisky (~£1 billion)
| Status | Tariff |
|---|
| Current | 10% |
| Previous (2018-2021) | 25% (Trump 1.0) |
Farm Machinery (£300 million)
| Status | Tariff |
|---|
| Current | 25%+ (derivative rules) |
| Largest export market | US |
UK Concessions
Beef Quota
| Provision | Detail |
|---|
| Duty-free quota | 13,000 metric tons |
| Additional | 1,000 tonnes at 0% (was 20%) |
Ethanol
| Provision | Detail |
|---|
| Duty-free volume | 1.4 billion liters |
| Previous tariff | 19% |
Pharmaceutical Pricing
| Commitment | Detail |
|---|
| NHS spending | 25% more on new treatments |
| Beneficiary | US pharma companies |
Estimated US Gains
| Value | Detail |
|---|
| New export opportunities | $5 billion |
| Market access | Beef, ethanol, pharma |
Digital Services Tax Dispute
Background
| Issue | Detail |
|---|
| UK DST | 2% tax on tech company revenues |
| Annual revenue | £800 million |
| US position | Demands removal |
Tech Prosperity Deal Crisis
| Date | Event |
|---|
| Sept 18, 2025 | Tech deal signed (£31B/$42B) |
| Dec 16, 2025 | Deal suspended over DST |
| Status | Negotiations January 2026 |
Impact
The DST dispute threatens broader trade relationship:
- Tech deal provisions on hold
- Potential escalation
- January 2026 negotiations planned
Outstanding Issues
Steel/Aluminum Quota
| Status | Detail |
|---|
| Current tariff | 25% |
| Negotiated outcome | 0% under quota |
| Progress | Still being finalized |
Digital Services Tax
Must be resolved for full EPD implementation
Other Unresolved
| Issue | Status |
|---|
| Financial services | Not covered |
| Online Safety Act | Regulatory concerns |
| Food safety standards | Alignment issues |
| Full FTA | Not achieved |
Significant Events
| Date | Event | Impact |
|---|
| Apr 5, 2025 | 10% tariff takes effect | Lower than EU |
| May 8, 2025 | EPD announced | Relief |
| Jun 30, 2025 | EPD provisions begin | Sector benefits |
| Dec 1, 2025 | Pharma agreement | 0% secured |
| Dec 16, 2025 | Tech deal suspended | DST dispute |
Current Status (January 2026)
What’s in Effect
- 10% baseline (lowest among major partners)
- 0% on aerospace
- 0% on pharmaceuticals (3 years)
- 25% on steel/aluminum (pending quota)
Advantages Over EU
- 5 percentage points lower base rate
- Broader pharma exemption
- Auto quota at 10%
- Bilateral deal flexibility
Outstanding Issues
- DST dispute threatens expansion
- Steel/aluminum quota not finalized
- Tech deal suspended
- Full FTA not achieved
Outlook
The UK secured the most favorable tariff treatment among major US trading partners, benefiting from post-Brexit negotiating flexibility and the “special relationship.” The 10% baseline rate is significantly better than the EU’s 15%. However, the Digital Services Tax dispute and suspended Tech Prosperity Deal show the fragility of the arrangement. The steel/aluminum quota negotiation and January 2026 DST talks will be critical.
Sources